These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 18507843)

  • 41. Idiopathic gastric acid hypersecretion presenting as a diarrheal disorder and mimicking both Zollinger-Ellison syndrome and Crohn's disease.
    Blonski WC; Katzka DA; Lichtenstein GR; Metz DC
    Eur J Gastroenterol Hepatol; 2005 Apr; 17(4):441-4. PubMed ID: 15756097
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Influence of lansoprazole on intragastric 24-hour pH, meal-stimulated gastric acid secretion, and concentrations of gastrointestinal hormones and enzymes in serum and gastric juice in healthy volunteers.
    Brunner G; Hell M; Hengels KJ; Hennig U; Fuchs W
    Digestion; 1995; 56(2):137-44. PubMed ID: 7750667
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Use of omeprazole in Zollinger-Ellison syndrome: a prospective nine-year study of efficacy and safety.
    Metz DC; Strader DB; Orbuch M; Koviack PD; Feigenbaum KM; Jensen RT
    Aliment Pharmacol Ther; 1993 Dec; 7(6):597-610. PubMed ID: 8161665
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Oral pantoprazole for acid suppression in the treatment of patients with Zollinger-Ellison syndrome.
    Désir B; Poitras P
    Can J Gastroenterol; 2001 Dec; 15(12):795-8. PubMed ID: 11773945
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Potential uses of intravenous proton pump inhibitors to control gastric acid secretion.
    Metz DC
    Digestion; 2000; 62(2-3):73-81. PubMed ID: 11025353
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Pantoprazole: an update of its pharmacological properties and therapeutic use in the management of acid-related disorders.
    Cheer SM; Prakash A; Faulds D; Lamb HM
    Drugs; 2003; 63(1):101-33. PubMed ID: 12487624
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Occurrence and relapse of bleeding from duodenal ulcer: respective roles of acid secretion and Helicobacter pylori infection.
    Capurso G; Annibale B; Osborn J; D'Ambra G; Martino G; Lahner E; Delle Fave G
    Aliment Pharmacol Ther; 2001 Jun; 15(6):821-9. PubMed ID: 11380320
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Lansoprazole--profile of a new proton pump inhibitor].
    Seifert E
    Leber Magen Darm; 1994 Mar; 24(2):66-8, 71. PubMed ID: 8196467
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Omeprazole in the Zollinger-Ellison syndrome.
    Bardram L; Stadil F
    Scand J Gastroenterol; 1986 Apr; 21(3):374-8. PubMed ID: 3715402
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Lansoprazol ++ : a new proton pump inhibitor].
    Baczek J; Laskowiec G
    Pol Merkur Lekarski; 1998 Jun; 4(24):339-41. PubMed ID: 9771021
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Lansoprazole: pharmacokinetics, pharmacodynamics and clinical uses.
    Gremse DA
    Expert Opin Pharmacother; 2001 Oct; 2(10):1663-70. PubMed ID: 11825309
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Lansoprazole. A review of its pharmacodynamic and pharmacokinetic properties and its therapeutic efficacy in acid-related disorders.
    Barradell LB; Faulds D; McTavish D
    Drugs; 1992 Aug; 44(2):225-50. PubMed ID: 1382017
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Second proton-pump inhibitor marketed.
    Am J Health Syst Pharm; 1995 Aug; 52(15):1601. PubMed ID: 7583820
    [No Abstract]   [Full Text] [Related]  

  • 54. Proton pump inhibitors: better acid suppression when taken before a meal than without a meal.
    Hatlebakk JG; Katz PO; Camacho-Lobato L; Castell DO
    Aliment Pharmacol Ther; 2000 Oct; 14(10):1267-72. PubMed ID: 11012470
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Consequences of long-term proton pump blockade: insights from studies of patients with gastrinomas.
    Jensen RT
    Basic Clin Pharmacol Toxicol; 2006 Jan; 98(1):4-19. PubMed ID: 16433886
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Initial potency of lansoprazole and omeprazole tablets on pentagastrin-stimulated gastric acid secretion-a placebo-controlled study in healthy volunteers.
    Müller P; Göksu MA; Fuchs W; Schlüter F; Simon B
    Aliment Pharmacol Ther; 2000 Sep; 14(9):1225-9. PubMed ID: 10971240
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Efficacy of long-term therapy with low doses of omeprazole in the control of gastric acid secretion in Zollinger-Ellison syndrome patients.
    Corleto V; Annibale B; D'Ambra G; Saggioro A; Ferrua B; Cassetta MR; Delle Fave G
    Aliment Pharmacol Ther; 1993 Apr; 7(2):167-73. PubMed ID: 8485270
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Optimal treatment of Zollinger-Ellison syndrome and related conditions in elderly patients.
    Tomassetti P; Salomone T; Migliori M; Campana D; Corinaldesi R
    Drugs Aging; 2003; 20(14):1019-34. PubMed ID: 14651442
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Prospective study of the need for long-term antisecretory therapy in patients with Zollinger-Ellison syndrome following successful curative gastrinoma resection.
    Metz DC; Benya RV; Fishbeyn VA; Pisegna JR; Orbuch M; Strader DB; Norton JA; Jensen RT
    Aliment Pharmacol Ther; 1993 Jun; 7(3):247-57. PubMed ID: 8364130
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Zollinger-Ellison syndrome. Relation to Helicobacter pylori-associated chronic gastritis and gastric acid secretion.
    Fich A; Talley NJ; Shorter RG; Phillips SF
    Dig Dis Sci; 1991 Jan; 36(1):10-4. PubMed ID: 1984995
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.